Pancreatic cancer (PC) is one of the most lethal cancers, with an overall 5 years survival rate of <5%. The clinical benefit of gemcitabine based chemotherapeutic strategy on PC was limited by its high drug resistance rate. Snail, one of the master regulators of epithelial-mesenchymal transition, has been implicated in the progression of various cancers. However, whether it is also linked to the development of chemosensitivity to gemcitabine in PC is unknown, and the regulatory pathways controlling Snail also need to be explored. Cell apoptosis analysis was performed using flow cytometry assay. Quantitative real-time PCR was used to investigate the level of microRNA and the mRNA expression of its target, Snail. Snail expression was measured by immunoblotting and immunohistochemistry. A xenografted tumor model was used to test the in vivo effects of miR-153 on chemosensitivity to gemcitabine. The results of this study demonstrated the decrease of miR-153 expression in PC tumor tissue, which is correlated with a poor prognosis. miR-153 mimic transfection enhanced gemcitabine sensitivity in gemcitabine-resistant PC cells, while downregulation of miR-153 decreased gemcitabine sensitivity. In addition, miR-153 was found to target the 3′-UTR of Snail mRNA. Furthermore, we found that the increase of apoptosis in gemcitabine-resistant PC cells resulted from miR-153 mimic transfection was reversed by overexpression of Snail. miR-153 reverses the resistance of PC cells to gemcitabine by directly targeting Snail, and it may be a potential novel therapeutic target for overcoming gemcitabine resistance in human PC.
Introduction
Pancreatic cancer (PC) is a common human malignant neoplasm and the fourth most common cause of cancer-related death in the United States [1] . Despite advances in surgery and adjuvant therapy, the prognosis of PC patients remains extremely poor, with a median survival of <1 year and, overall, a 5-year survival rate of <5% [2] .
The current standard treatment for patients with advanced PC is radical surgical resection followed by chemotherapy. Gemcitabine, a nucleoside analog, is the only first-line chemotherapeutic agent used in PC patients for more than a decade. However, only <20% PC patients are sensitive to gemcitabine, and this highly resistance rate made PC treatment especially difficult [3, 4] . Therefore, elucidating the molecular mechanisms underlying gemcitabine-resistance may improve the clinical outcomes for PC patients. miRNAs are a class of endogenous non-coding RNAs (17~25 nucleotides), which could regulate multiple biological processes by inducing the degradation of protein-coding genes [5] . Aberrant miRNA expression has been observed in multiple diseases, especially in cancers [6] [7] [8] [9] [10] . The pivotal roles of miRNAs in tumor chemoresistance have been consistently reported [11] [12] [13] [14] . Furthermore, recent studies have revealed that epithelial-mesenchymal transition (EMT) is actively involved in the mechanisms of drug resistance in PC [15, 16] . Many transcription factors, including Snail, Slug, Twist, and Zeb-1, have been identified as master regulators of phenotypic changes during the EMT process [17] [18] [19] . miR-153, a tumor suppressor, is reported to be capable of regulating EMT through targeting Snail [20] [21] [22] [23] . This regulatory mechanism has been found to be involved in modulating tumor metastasis. However, the involvement of miR-153 in PC chemoresistance has not been investigated to date.
In this study, we found that miR-153 was downregulated in PC cells and tissues. Moreover, miR-153 expression was highly correlated with the status of PC chemoresistance. miR-153 directly targeted the EMT master gene Snail. Downregulation of miR-153 increased Snail expression, which can eventually lead to PC chemoresistance. Altogether, our results suggest that miR-153 plays a significant role in PC chemotherapeutic sensitivity and might be a promising target for improving PC therapeutic efficacy.
Materials and Methods

Tissue samples
Tissues were collected from 87 patients harboring histologicallyconfirmed pancreatic ductal adenocarcinoma, who had undergone radical mastectomy of the tumor and received postoperative adjuvant chemotherapy (gemcitabine-based) at the General Surgery (Huashan Hospital, Fudan University, Shanghai, China) from January 2010 to December 2014. Fresh tumor samples were collected immediately after surgical removal, then snap-frozen in liquid nitrogen and stored at −80°C prior to total RNA extraction. The time from surgery to last follow-up or death was calculated as postoperative survival. Collection and analysis of patient samples were approved by the Ethical Committee of Huashan Hospital, and written informed consents were obtained from all patients.
Cell culture
Human pancreatic carcinoma cell lines (BxPC-3, Panc-1, Capan-2, SW1990, Paca-2, AsPc-1, and CFPAC-1), human pancreatic ductal epithelial cell line (HPDE), and human embryonic kidney cell line (HEK293T) were purchased from the American Type Culture Collection (Manassas, USA). HEK293T cells were cultured in Dulbecco's modified Eagle medium (Gibco, Carlsbad, USA), and RPMI 1640 (Gibco) was used for culturing pancreatic carcinoma cells and pancreatic ductal epithelial cells. Fetal bovine serum (10%) and antibiotics were added. Cells were cultured at 5% CO 2 and 37°C. Adenovirus amplification was performed using HEK293T. Gemcitabine was dissolved in dimethyl sulfoxide.
Generation of gemcitabine-resistant PC cells
Capan-2, Panc-1, and AsPc-1 cells were treated with gradually increasing concentrations of gemcitabine for 1 month. The initial gemcitabine concentration was 0.1 μM. When cells adapted to the drug, the gemcitabine concentration was increased. The final gemcitabine concentration applied to Capan-2, Panc-1, and AsPc-1 cells was 0.2, 10, and 100 μM, respectively. Viable cells remaining attached to the dish at the final gemcitabine concentration treatment were considered to be gemcitabine resistant and were collected for subsequent experiments.
Cell transfection
A human miR-153 expression vector was constructed by inserting the coding sequence of miR-153 into pCDH-CMV-MCS-EF1-copGFP (System Biosciences, Palo Alto, USA). Recombinant lentiviruses were generated by transient transfection of HEK293T cells, along with package vectors, using Lipofectamine 2000 (Invitrogen, Carlsbad, USA). Forty-eight hours after transfection, the viruses were harvested and viral titers were determined. AsPc-1 cells were then infected with lentiviruses in the presence of 4 μg/ml polybrene (Sigma, St Louis, USA), followed by puromycin selection (2 μg/ml). The miR-153 mimic, miR-153 inhibitor (antisense miR-153, AsmiR-153) and siRNA of Snail were purchased from GenePharma (GenePharma, Shanghai, China). Cells were cultured to 60%-70% confluence in six-well plates, followed by miR-153, miR-153 mimic, miR-153 inhibitor, and Snail siRNA (50 nM) transfection
Quantitative real-time PCR analysis
Total RNA was isolated from cells or fresh tissue samples using TRIzol Reagent (Invitrogen). microRNAs were extracted from cells or fresh tissue samples using an miRNeasy Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. RNA quality and quantity were assessed using a NanoDrop ND-8000 spectrophotometer (Thermo Fisher Scientific, Waltham, USA) at 260 and 280 nm (A 260/280 ) wavelengths. cDNA was synthesized using a Reverse Transcriptase M-MLV kit (Applied Biosystems, Foster City, USA). The quantitative real-time PCR (qPCR) was Table 1 . Sequence of primers used for qPCR
Genes (Homo sapiens)
Primers Sequence
RT, reverse transcription.
performed with SYBR Premix Ex Taq (TaKaRa, Dalian, China) and run with an Applied Biosystems ViiATM 7 Real-Time PCR System (Applied Biosystems). The expression data for the target miRNA and mRNA were analyzed using the 2 −ΔΔCT method, and normalized to an endogenous control, U6 and GAPDH. The primer sequences used for qPCR are listed in Table 1 .
Immunoblot analysis
Immunoblotting experiments were conducted according to manufacturer's instructions. Cells were lysed in lysis buffer supplemented with protease inhibitors. Protein concentration was determined by the bicinchoninic acid method. Equal amounts of cell lysates were subjected to electrophoresis on 10% Bis-Tris gels and transferred onto PVDF membranes (Millipore, Billerica, USA). Membranes were probed with the indicated primary antibodies against Snail and β-actin (Abcam, Cambridge, USA) overnight at 4°C, followed by horseradish peroxidase (HRP)-conjugated secondary antibodies (Promega, Madison, USA). Images of target proteins were detected by chemiluminescence HRP substrate kit (Millipore) and ImageQuant LAS 4000 (GE Healthcare Life Science, Bethesda, USA).
MTS assay
The (3-carboxymethoxyphenyl)-2-(sulfophenyl)-2 H-tetrazolium (MTS; Promega) assay was used to determine cell viability. Briefly, cells were seeded into 96-well plates (5 × 10 3 cells/well) and incubated overnight.
Gemcitabine was added to cells for 48 h at a range of different concentrations. The MTS reagent was then added, and incubated at 37°C in a humidified, 5% CO 2 atmosphere for further 2 h. Finally, the absorbance was read at 490 nm using a Synergy 2 plate reader (Biotek, Winooski, USA). The data of cell viability was recorded as a percentage relative to the control group.
Cell apoptosis assay
Cell apoptosis was determined using an Annexin-V/PI Apoptosis Detection Kit (BD Biosciences, San Diego, USA) according to manufacturer's instructions. Cells were seeded into six-well plates and grown to~60% confluence. They were then treated with gemcitabine for 48 h. After that, floating and attached cells were harvested and incubated with Annexin-V/PI for 15 min in the dark, and analyzed by fluorescence activated cell sorting. All experiments were performed in triplicate.
Luciferase assay
Cells were seeded into 24-well plates (4 × 10 4 cells/well). Twenty-four hours later cells were transfected with miR-153 mimic or control microRNA. pGL3-Snail-3′-UTR-wild type or pGL3-Snail-3′-UTRmutant luciferase plasmid (Promega; 100 ng), together with pRL-TK Renilla plasmid (Promega; 5 ng) were transfected using Lipofectamine Pearson's correlation analysis was used. U6 small nuclear RNA was used as an internal control in qPCR. ***P < 0.001. Luciferase and Renilla signals were measured at 36 h after transfection using Dual Luciferase Reporter Assay Kit (Promega) according to the manufacturer's protocol.
Immunohistochemistry assay
For immunohistochemistry, PC patient tissues and subcutaneous xenografts fixed in 10% buffered formalin were embedded in paraffin blocks, and then were sectioned into 4-μm sections. Sections were treated with xylene to remove paraffin, and dehydrated by gradient alcohol, followed by treating with an antigen retrieval agent before blocking nonspecific signals. Slides were then incubated with a human anti-Snail antibody (Abcam) at a 1:400 dilution followed by an HRP-conjugated anti-rabbit immunoglobulin antibody using a Histostain-Plus Kit (Haoran-Bio, Shanghai, China). Negative controls were incubated with PBS instead of the specific primary antibody. Positive staining cells were visualized by with ImmPRESS Peroxidase Polymer Detection Reagents (Vector Laboratories, Burlingame, USA) and 3,3′-diaminobenzidine (DAB). Five sections per tumor tissue were examined.
Terminal deoxynucleotidyl transferase dUTP nick end labeling assays
For the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, tumor tissue was fixed in 10% formalin before being embedded in paraffin and cut into 4-μm thick sections. An In Situ Cell Death Detection Kit, POD (Roche, Indianapolis, USA) was used to detect cellular apoptosis in tumor tissues according to the manufacturer's instructions. Cells with brown staining were counted as apoptotic cells. The data were quantified as percentage of TUNEL-positive cancer cells.
Xenografted tumor model
Twenty-four BALB/c-nu mice (3-4 weeks old, 18-20 g) were purchased from the Experimental Animal Center of the Shanghai Lab Animal Research Center (Shanghai, China) and housed in barrier facilities on a 12-h light/dark cycle. The process was strictly preformed according to the guidelines of the Animal Care and Use Committee of Fudan University for Animal Maintenance and Experimental Procedures. The mice were randomly divided into four groups (Vector + Saline, miR-153 + Saline, Vector + Gemcitabine, and miR-153 + Gemcitabine) (n = 6 for each group). When the tumor volume reached 250-300 mm 3 , gemcitabine (50 mg/kg) or saline was administered weekly (on the 14th, 21st, 28th, and 35th day). The tumor length, width, and thickness were measured every 4 days using callipers. Tumor volume was calculated using the equation (L × W 2 )/2. On Day 38, animals were euthanized, tumors were excised, weighed, and paraffin-embedded for betweengroup comparisons and for analysis using the TUNEL assay.
Statistical analysis
The data were presented as the mean ± standard error of the mean (SEM). Statistical comparisons between two different groups were made using an unpaired two-tailed Student's t-test. The relative expression of miR-153 or Snail mRNA in PC tissues was categorized into low and high miR-153 or Snail expression group using the median value as cut-off. Survival probabilities were determined using the Kaplan-Meier estimator and compared using a log-rank test. GraphPad Prism 6.0 software (GraphPad Software, USA) was used for all statistical analyses. P < 0.05 was considered statistically significant. 
Results
Expression of miR-153 in PC cell lines and tissues
The expression of miR-153 in PC and normal HPDE cell lines were examined by qPCR. As shown in Fig. 1A , miR-153 expression was significantly lower in all PC cell lines including BxPC-3, Panc-1, Capan-2, SW1990, Paca-2, AsPc-1, and CFPAC-1, compared with HPDE cells. To further confirm the association between miR-153 and PC, we measured the miR-153 levels in 87 paired tissues removed from PC tumors and adjacent normal tissues. It was found that, like PC cell lines, PC tissue also exhibited lower miR-153 levels compared with paired normal tissue (Fig. 1B) .
Reduced miR-153 expression is correlated with poor prognosis and gemcitabine resistance
To explore whether miR-153 expression was associated with clinicopathological parameters, we collected detailed information for each patient, including age, gender, tumor size, histopathological grading, degree of tumor differentiation, tumor location, evidence of lymph node metastasis, and TNM staging. Analysis of data showed that there was no association between the levels of miR-153 expression and clinicopathological features ( Table 2) . However, the low miR-153 expression in tumor tissues from 87 PC patients that received a postoperative gemcitabine-based treatment was significantly associated with the poorer cumulative survival rate (P = 0.007; HR = 1.97; 95% CI = 1.20-3.23) (Fig. 1C) . In order to find out how miR-153 expression is correlated with PC prognosis, we established three gemcitabine-resistant PC cell lines (Capan-2-GR, Panc-1-GR, and AsPc-1-GR) and then compared miR-153 expression between normal cells and gemcitabine-resistant cells. Interestingly, lower miR-153 expression was detected in the gemcitabine-resistant cell lines, Capan-2-GR, Panc-1-GR, and AsPc-1-GE (Fig. 1D) , which suggested that reduced miR-153 might relate to PC chemotherapeutic efficacy. To confirm this, the IC 50 of gemcitabine was compared to miR-153 expression in all 11 PC cell lines (Fig. 1E) . A reverse relationship between miR-153 expression and gemcitabine cytotoxicity was observed (P < 0.001, r = -0.864) (Fig. 1F) . These results suggest that reduced miR-153 expression might decrease the sensitivity of PC cells to gemcitabine therefore resulting in poor prognosis.
miR-153 regulates the chemosensitivity of gemcitabine in PC cells
To further clarify the effect of altered miR-153 expression on PC sensitivity to gemcitabine, miR-153 inhibitor was used in normal PC cell lines (Capan-2, Panc-1, and AsPc-1) to reduce miR-153 expression, prior to the treatment with gemcitabine. Interestingly, the downregulation of miR-153 expression enhanced cell resistance to gemcitabine, with a significant reduction in IC 50 ( Fig. 2A-C) . In contrast, the overexpression of miR-153, achieved by transfecting miR-153 mimic into gemcitabine-resistant cell lines (Capan-2-GR, Panc-1-GR, and AsPc-1-GR), successfully restored their sensitivity to gemcitabine (Fig. 2D-F) . However, miR-153 had no effect on the viability of the PC cell lines in the absence of gemcitabine (Fig. 2G-I) . The above results suggest that miR-153 is a reliable candidate for mediating PC chemoresistance.
Snail is a miR-153 target gene in PC cell lines
MiRNAs mainly exert their function through binding to the 3′-UTR of their target genes to regulate their expression. Using TargetScan Release 7.0, we found that the 3′-UTR of the Snail is predicted to possess a putative binding site for miR-153. In order to find out the possible relationship between miR-153 and Snail, we knocked down miR-153 in Panc-1, AsPc-1, and Capan-2 cell lines, or overexpressed Luciferase activity analysis of Snail-3′-UTR was performed after cotransfection with Snail-wild-type or Snail-mutant pGL3 constructs and miR-153 mimic using the Dual-luciferase Reporter Assay System. GAPDH was used to normalize the qPCR results. All experiments were repeated four times. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant.
it in the corresponding gemcitabine-resistant cell lines. Reduced miR-153 consistently increased Snail expression in Panc-1, AsPc-1, and Capan-2 cell lines while miR-153 overexpression had the opposite effect on the three gemcitabine resistant cell lines (Fig. 3A-C) . To elucidate how Snail is regulated by miR-153, we then cloned the predicted miR-153 binding site on Snail gene into a pGL3 luciferase reporter vector, and examined the luciferase activity in Panc-1 and Panc-1 gemcitabine-resistant cell lines supplemented with either miR-153 mimic or miR-153 inhibitor. In addition, a mutant Snail-3′-UTR reporter construct harboring four point mutations in the center of the putative miR-153-response element was also generated (Fig. 3D) . In the wild-type counterpart, the miR-153 mimic strongly suppressed luciferase activity while the miR-153 inhibitor increased it. However, all of these effects were abrogated in the mutant group (Fig. 3E) . These results further support that reduced miR-153 expression increased PC chemoresistance through increasing Snail expression.
miR-153 regulates the sensitivity of gemcitabine through Snail
As reduced miR-153 expression was correlated with increased Snail expression in vitro, we further confirmed these results in vivo. Both elevated Snail mRNA and protein expression were found in PC tissues (Fig. 4A,B ). An adverse relationship was also found between Snail expression and miR-153 expression in PC tissues and normal pancreatic tissue (Fig. 4C) . The increase in the chemosensitivity to gemcitabine following mimic miR-153 treatment could be rescued by overexpression of Snail in gemcitabine-resistant cells (Capan-2-GR, Panc-1-GR, and AsPc-1-GR) (Fig. 4D) . Furthermore, patients with increased Snail expression had a lower cumulative survival rate (P = 0.037; HR = 1.50; 95% CI = 0.96-2.44) than those with less Snail expression (Fig. 4E) . These results showed that miR-153 could enhance the therapeutic effect of gemcitabine through Snail in PC cells.
miR-153 overexpression increases gemcitabine therapeutic efficacy in vivo
To investigate the effect of miR-153 on gemcitabine-sensitivity in vivo, Panc-1 cells stably transfected with an miR-153 plasmid construct or control plasmid were injected subcutaneously into male nude mice. Until tumor presentation, one group was treated with gemcitabine (50 mg/kg per week) administered by intraperitoneal injection, and the other group was treated with the carrier only. There was no difference in the tumor volume between the control group and the miR-153 overexpression group (Fig. 5A-C) . However, a significant difference was observed following gemcitabine treatment ( Fig. 5A-C) .
Immunohistochemistry and qPCR analysis of Snail protein and mRNA expression levels confirmed that miR-153 can down-regulate Snail expression (Fig. 5D ,E,G). TUNEL analysis of the tumor specimens confirmed an increased apoptosis rate in tumors of the Annexin-V/PI staining was used detect the rate of apoptosis of PC cells after co-transfection with mimic miR-153 and Snail-overexpression plasmid, followed by exposure to gemcitabine for 48 h. (E) Kaplan-Meier curves of postoperative survival for PC patients with high/low Snail expression. U6 small nuclear RNA and GAPDH were used to normalize the qPCR results. All experiments were repeated four times. *P < 0.05; **P < 0.01; ***P < 0.001.
miR-153-transfected group when compared with that in tumors of the empty vector-transfected group in response to gemcitabine (Fig. 5F , G). The results from tumor xenograft mouse models provide further evidence that miR-153 enhances gemcitabine-induced apoptosis.
Discussion
Considering that the poor prognosis of PC patients is still observed, the exploration of mechanisms underlying the pronounced chemoresistance and the development of novel therapeutic strategies for overcoming drug resistance is a prerequisite to achieve better clinical outcomes. In the present study, we first showed that miR-153 expression was significantly downregulated in PC tissues and gemcitabine-resistant PC cell lines. The addition of miR-153 could reverse the gemcitabine resistance in PC cells, while inhibition of miR-153 could decrease the sensitivity of PC cells to gemcitabine. Furthermore, miR-153 could increase gemcitabine-sensitivity in PC cells through directly targeting Snail, for its degradation. Our study identified a novel microRNA implicated in PC chemoresistance, which might provide a reliable target for future clinical treatment. Representative images from six separate samples were shown. Scale bars, 50 μm; *P < 0.05; **P < 0.01; ***P < 0.001.
Aberrant miRNA expression has been found in various types of cancer and is involved in cell proliferation, cell invasion, and chemosensitivity. Accumulating evidence suggests that miR-153 expression is reduced in malignant cancers and miR-153 is capable of targeting various tumor-associated genes [20] [21] [22] [23] [24] . For instance, Xu et al. [20] claimed that miR-153 downregulation is correlated with hyperproliferation capacity or increased metastasis of a human epithelial cancer. Functional studies showed that elevated miR-153 expression could inhibit EMT, suppress TGF-β mediated proliferation and migration, and promote β-catenin transcriptional activity. In addition, Liu et al. [25] reported that miR-153 was downregulated in As 2 O 3 -induced drug-resistant K562 cells and leukemic stem cells. Forced expression of miR-153 in K562 cells had significant effects on the chemosensitivity of As 2 O 3 . However, the underlying connection between miR-153 and gemcitabine chemoresistance has not yet to be fully elucidated. In order to identify the underlying mechanisms for chemotherapy resistance, we performed qPCR to measure miR-153 expression and confirmed that it was reduced dramatically in PC tissue samples and the gemcitabine-resistant cell lines Capan-2, Panc-1, and AsPc-1. Interestingly, miR-153 expression was not associated with clinicopathological parameters, except for the prognosis of PC patients receiving a gemcitabine-based therapy. We then analyzed the effects of miR-53 expression on the gemcitabine sensitivity of PC cells by gain-and loss-of-function assays. Upregulation of miR-153 could reverse gemcitabine resistance in PC cells by enhancing gemcitabineinduced apoptosis, while inhibition of miR-53 could induce gemcitabine resistance in parental PC cells by reducing gemcitabine-induced apoptosis.
Generally, miRNAs display their biological function via binding to the 3′-UTR of their specific target genes to suppress their expression [26] . To identify the target genes of miR-153, more than 877 transcripts with conserved sites were predicted using the online bioinformatics analysis, Targetscan. Given the results of this analysis together with those from previous studies on miR-153 targets and the functions of these prediction genes, we decided to focus on Snail. Snail has been considered as a critical pro-metastatic factor in various tumors by inducing EMT, and more recently it has also been shown to participate in the process of chemoresistance. By using a dual-luciferase reporter assay, we confirmed that Snail is a target of miR-153. We also found that Snail was inversely regulated by miR-153, and confirmed that it was a direct functional target of miR-153 in gemcitabine-resistance PC cells. Furthermore, we showed that miR-153 was negatively correlated with the expression of Snail mRNA in both PC tissue and adjacent normal tissue, and that Snail was also a marker of prognosis in PC patients receiving gemcitabinebased therapy. Recently, a study from Bai et al. [27] showed that miR-153, an independent prognostic marker for predicting survival rate of PC patients, inhibited cell migration and invasion by targeting Snail. Consistently, our results show that miR-153/Snail axis is also implicated in drug resistance of PC cells, which provides more clues for future discovery of potential clinical therapeutic targets. Therefore, we suggest that miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in PC.
In summary, our investigation suggests that decreased expression of miR-153 in human PC might be significant in the acquisition of a drug-resistant phenotype, suggesting that miR-153 functions as a suppressor in PC progression and might serve as a novel prognostic and therapeutic biomarker for PC. Furthermore, miR-153 could significantly affect PC gemcitabine-sensitivity through downregulating Snail. Therefore, targeting miR-153-Snail signaling may be a potential strategy for reversing chemoresistance and hence in combating PC.
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